SLC5A1 and chronic kidney disease: Sotagliflozin was recently approved by the FDA as a dual SGLT1/SGLT2 inhibitor to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors (Packer, 2023).